Needlestick injuries are one of the most frequent accidents in hospitals and they can be particularly dangerous for healthworkers if there are contaminants involved, such as HBV, HCV or HIV.

Greiner Bio-One has released the VACUETTE EVOPROTECT safety blood collection set in an effort to prevent needlestick injuries during blood collection. The semi-automatic click mechanism protects the user from the risk of needlestick injuries and makes the daily task of blood collection easier. The safety triggers located on the side of the device facilitate one-handed activation. The needle is then automatically retracted and, at the same time, safely and irreversibly enclosed in the safety shield. A clearly audible click confirms that the safety mechanism is successfully activated.

The safety blood collection set meets current safety requirements and provides substantial support for safe blood collection and infusion with the same set.

• For more information, visit: gbo.com or www.power4safety.com.

Philips showcased the Philips Patient Flow Capacity Suite and Philips Acute Care Telehealth at HIMSS21 in Las Vegas this week. These two new HealthSuite solutions allow health systems to integrate informatics applications that can be combined and scaled according to need. They are secure, cloud-based and intended to break down barriers across patient care in a cost-effective model. The solutions, Philips says, help health systems deliver on the aim of a connected, protected, future-ready and cost-predictive single-cloud infrastructure and Software-as-a-Service (SaaS) model.

• Patient Flow Capacity Suite: A patient logistics solution that helps manage the patient journey across the entire care continuum. By taking a holistic approach to care coordination and combining clinical and operational data, the solution helps to provide the visualization and machine learning supported analytics that can enable more informed patient flow decisions. Care is orchestrated in a structured manner across the entire healthcare network, including affiliate networks as well as post-acute settings. Patient Flow Capacity Suite connects the front lines with hospital enterprise operations to systematically predict demand, make patient transition decisions, and spot patient flow bottlenecks.
• Acute Care Telehealth: Building on Philips’ decades-long expertise in Tele-ICU solutions, Acute Care Telehealth provides a configurable and flexible solution to help health systems realize their virtual care and wider enterprise telehealth ambitions. The solution’s scalability allows health systems to deploy Acute Care Telehealth in a centralized command centre, or a decentralized model of telehealth dependent on their needs. By allowing customers to add additional hospitals, clinical units or beds, Acute Care Telehealth grows as each organization’s telehealth strategy evolves.

Additional clinical and operational solutions will be added to Philips HealthSuite. Next, updates are planned for Philips Electronic Medical Record and Philips Acute Care and Anesthesia Workspace.

Driving connected, future-ready care

As care settings expand beyond the hospital, health systems are seeking new ways to manage the influx of data while addressing challenges with IT resources and budgets. The adoption of platform-based IT models is on the rise, with more than 30% of global economic activity expected to be mediated by digital platforms in six years, yet experts estimate only 3% of companies have adopted an effective platform strategy [1].

Philips HealthSuite securely stores critical healthcare data and provides both advanced analytics and AI capabilities, while delivering industry-leading interoperability to help enable precision care and provide care anywhere. With these new HealthSuite solutions, health systems can liberate data from silos and connect it in a way that enables care teams to turn data into actionable insights and collaborate to better serve patients.

“Health systems today must continue to evolve to meet the needs of patients and providers, ensuring care is connected across settings and that care can be delivered anywhere – all of which requires agile and secure platforms that will allow them to innovate and scale as demands shift,” said Roy Jakobs, Chief Business Leader, Connected Care, Philips. “Our cloud-based HealthSuite solutions are a milestone in how they support the acceleration of digital transformation in health systems to deliver better, patient-centric care, while reducing costs and resources.”

Modular approach

Using a modular approach, Philips offers flexible solutions and services to solve specific customer needs, making solutions easy to implement, install, maintain, and use. All solutions benefit from the same SaaS model, which can help to lower initial deployment costs and relieve ongoing IT resource strains.

Digital transition

Philips’ informatics solutions are an integral part of Philips Care Collaboration (currently available only in North America), a collaborative approach to supporting a healthcare organization’s digital transformation. As health systems seek to manage, coordinate, orchestrate and synchronize care across the health continuum, each organization’s digital journey will be unique. Through Care Collaboration, Philips acts as a partner to healthcare organizations to gain a deep understanding of their challenges and determine how Philips’ advanced HealthSuite solutions can help them support data and workflows to deliver enhanced patient care.

Reference

[1] Schenker, J. (2019, January 28). The Platform Economy. Retrieved November, 2020, from https://innovator.news/the-platform-economy-3c09439b56a.

Endologix, a California-based, global medical device company focussed on the treatment of vascular disease, says the company’s ChEVAS (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough Device Designation from the US FDA. The ChEVAS System is an investigational endovascular abdominal aortic aneurysm (AAA) sealing therapy designed to combine the Nellix 3.5 endograft with parallel visceral stents to enable treatment of patients with juxtarenal, pararenal and suprarenal AAA.

The FDA Breakthrough Devices Program gives patients more timely access to medical devices that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Breakthrough Devices receive priority review by FDA, and the program provides opportunities for early interaction with FDA personnel to expedite the review and approval process.

ChEVAS is currently being evaluated through the ChEVAS ONE IDE (Investigational Device Exemption) clinical study that is approved to enrol approximately 120 patients at up to 50 clinical sites worldwide. The national principal investigators of the ChEVAS ONE study are Francis Caputo, MD (Cleveland Clinic Foundation); William Jordan, MD (Emory University School of Medicine); Joseph Lombardi, MD (Cooper University Health Care) and William Quinones-Baldrich, MD (UCLA).

“The aneurysm sac sealing technology featured in the ChEVAS system is designed to reduce endoleaks, including gutter endoleaks, that are reported after endovascular treatment of complex aneurysms,” explained James McKinsey, MD, the leading enroller in the ChEVAS ONE IDE study. “Our initial clinical results of this therapy have been promising in a challenging group of patients.”

Dr. McKinsey will present his initial experience with ChEVAS at the Eastern Vascular Society Annual Meeting on September 26.

Matt Thompson, MD, chief medical officer at Endologix, said: “The ChEVAS System represents an important therapy that provides an ‘off-the shelf’ treatment to an underserved patient population who have complex abdominal aortic aneurysms. We are delighted that the FDA has designated ChEVAS as a Breakthrough Device, as this will facilitate our ability to develop this technology and make it available to patients in an expedited fashion. The ChEVAS System joins the PQ Bypass DETOUR System as the two FDA-designated Breakthrough Devices in our clinical investigational programs, which is reflective of our aspiration to provide innovative and disruptive technologies to address clinically relevant therapeutic gaps.”

• For more information, visit: http://www.endologix.com/

Lumenis, a medical device company renowned for developing and commercializing innovative energy-based technologies, including laser, intense pulsed light (IPL) and radio frequency (RF), for surgical, aesthetic, and ophthalmic applications, notes that all the hospitals named to U.S. News and World Report’s Best Hospitals Honor Roll use Lumenis surgical lasers. Most of them use the company’s flagship products: Lumenis MOSES holmium laser technology and the pioneering Lumenis UltraPulse DUO CO₂ surgical laser system.

The Lumenis holmium laser with MOSES technology delivers many clinical and economic advantages for kidney stones [1] and enlarged prostate [2] – two common procedures in many hospitals. Nearly universal adoption among these 20 top hospitals shows the strong trend toward standardization to MOSES technology. With MOSES, surgeons ablate stones with up to 85% higher efficiency [3] and 20% shorter procedure times [1].

For enlarged prostate surgery, MOSES has turned gold-standard HoLEP surgery from an overnight stay into a same-day, catheter-free discharge, [4] creating a better patient experience while freeing  hospital beds for acute care. Similarly, the tissue-sparing precision of the UltraPulse DUO CO₂ laser has revolutionized challenging procedures, such as transoral microsurgery and minimally invasive treatment of uterine fibroids and endometriosis. Lumenis lasers offer multi-specialty flexibility in busy medical centres, with applications in urology, gynaecology, otolaryngology, neurology and orthopaedics.

“We are pleased to see every one of the outstanding hospitals on the Best Hospitals Honor Roll uses Lumenis surgical lasers,” said Tzipi Ozer-Armon, CEO, Lumenis. “At Lumenis, our mission is to deliver better technology for better patient care. We believe that one way to achieve this is through innovation and collaboration with leading surgeons and hospitals around the world. The end result is that Lumenis technologies are helping exceptional hospitals deliver exceptional patient care.”

References

1. Ibrahim A et al. Double-Blinded Prospective Randomized Clinical Trial Comparing Regular and MOSES Modes of Holmium Laser Lithotripsy. J Endourology. 2020;34(5):624-628.

2. Kavoussi NL et al. MOSES Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Control Trial. J Urol. 2021 Feb 22.

3. Bench test results may not necessarily be indicative of clinical performance.

4. Agarwal DK et al. Same Day Discharge is a Successful Approach for the Majority of Patients Undergoing Holmium Laser Enucleation of the Prostate. Eur Urol Focus. 2021 Jan 4;S2405-4569(20)30320-5.

• For more information, visit lumenis.com.

NDD Medical Technologies (NDD), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has updated the entire EasyOne® product range, including the EasyOne Air, Easy on-PC, EasyOne Pro, and EasyOne Pro LAB, to be compliant with the ATS/ERS Standardization of Spirometry 2019.